+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Lymphoma"

From
From
From
BCL-2 (b-cell Lymphoma 2) Inhibitors Market 2024-2028 - Product Thumbnail Image

BCL-2 (b-cell Lymphoma 2) Inhibitors Market 2024-2028

  • Report
  • July 2024
  • 175 Pages
  • Global
From
From
From
Oncology Collaboration and Licensing Deals 2019-2024 - Product Thumbnail Image

Oncology Collaboration and Licensing Deals 2019-2024

  • Report
  • October 2024
  • 1800 Pages
  • Global
From
From
Immuno-Oncology - Global Strategic Business Report - Product Thumbnail Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • March 2025
  • 224 Pages
  • Global
From
Hematological Malignancies - Global Strategic Business Report - Product Thumbnail Image

Hematological Malignancies - Global Strategic Business Report

  • Report
  • March 2025
  • 193 Pages
  • Global
From
Oncology Based in-Vivo CRO Market Report 2025 - Product Thumbnail Image

Oncology Based in-Vivo CRO Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Loading Indicator

Lymphoma is a type of hematological malignancy that originates in the lymphatic system. It is characterized by the uncontrolled growth of lymphocytes, a type of white blood cell. Lymphomas can be either Hodgkin's or non-Hodgkin's, and can be either indolent or aggressive. Treatment options for lymphoma include chemotherapy, radiation therapy, stem cell transplantation, and targeted therapies. The lymphoma market is a subset of the larger hematology market, which includes treatments for a variety of blood-related diseases. The lymphoma market is driven by the increasing prevalence of the disease, as well as the development of new treatments. Companies in the lymphoma market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Gilead Sciences, Novartis, and Pfizer. Show Less Read more